title: A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial.
abstract: OBJECTIVE
  Small reference vessel diameter predicts adverse outcomes following coronary stenting. TAXUS Express and TAXUS Liberté paclitaxel-eluting stents (PES) reduce restenosis compared to bare metal stents (BMS) in small diameter vessels. TAXUS Element is a novel thin-strut, platinum chromium stent designed to enhance visibility, conformability, and drug delivery in small diameter vessels.
  
  
  RESULTS
  The PERSEUS Small Vessel (SV) prospective, single-arm, superiority trial evaluates the TAXUS Element PES in 224 subjects with target lesion length≤20 mm and vessel diameter≥2.25 to <2.75 mm, compared to 125 lesion-matched historical Express BMS control subjects from the TAXUS V trial. The primary endpoint was nine-month in-stent late loss. The secondary endpoint was 12-month target lesion failure (TLF) compared to a pre-specified performance goal (PG). Outcomes were analysed with and without propensity-score adjustment. TAXUS Element was superior to the Express BMS for late loss (0.38±0.51 versus 0.80±0.53 mm respectively; P<0.001), and TLF (7.3%) was significantly less than the 19.5% PG (P<0.001). No differences in mortality, myocardial infarction, or stent thrombosis were observed through 12 months. Results were similar after adjustment.
  
  
  CONCLUSIONS
  PERSEUS SV supports the efficacy and safety of the platinum chromium, thin-strut TAXUS Element stent in small coronary vessels.
authors.affiliation: Cardiac and Vascular Research Center of Northern Michigan, Northern Michigan Regional Hospital, Petoskey, MI, USA.
authors.forename: Louis A
authors.initials: LA
authors.lastname: Cannon
authors.forename: Dean J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: Tift
authors.initials: T
authors.lastname: Mann
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Michael R
authors.initials: MR
authors.lastname: Mooney
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Mishkel
authors.forename: Tommy C
authors.initials: TC
authors.lastname: Lee
authors.forename: B Hadley
authors.initials: BH
authors.lastname: Wilson
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Stuckey
authors.forename: Steven
authors.initials: S
authors.lastname: Orlow
authors.forename: Thomas
authors.initials: T
authors.lastname: McGarry
authors.forename: Michael E
authors.initials: ME
authors.lastname: Ring
authors.forename: Mirle A
authors.initials: MA
authors.lastname: Kellett
authors.forename: Paul
authors.initials: P
authors.lastname: Underwood
authors.forename: Keith D
authors.initials: KD
authors.lastname: Dawkins
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality; D017608:Chromium Compounds; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000401:mortality; D003331:Coronary Vessels / Q000187:drug effects; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D019544:Equipment Failure Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D017671:Platinum Compounds; D011446:Prospective Studies
chemical_list: D017608:Chromium Compounds; D017671:Platinum Compounds; D017239:Paclitaxel